Skip to main content
Clinical Trials/NCT03226522
NCT03226522
Completed
Phase 2

A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type

Axsome Therapeutics, Inc.2 sites in 2 countries366 target enrollmentJuly 13, 2017

Overview

Phase
Phase 2
Intervention
AXS-05
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Sponsor
Axsome Therapeutics, Inc.
Enrollment
366
Locations
2
Primary Endpoint
Change in CMAI Total Score
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.

Registry
clinicaltrials.gov
Start Date
July 13, 2017
End Date
April 17, 2020
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria.
  • Diagnosis of clinically signification agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation.

Exclusion Criteria

  • Patient has dementia predominantly of non-Alzheimer's type.
  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.

Arms & Interventions

AXS-05

AXS-05 tablets taken by mouth for 5 weeks.

Intervention: AXS-05

Bupropion

Bupropion tablets taken by mouth for 5 weeks.

Intervention: Bupropion

Placebo

Placebo tablets taken by mouth for 5 weeks.

Intervention: Placebo

Outcomes

Primary Outcomes

Change in CMAI Total Score

Time Frame: 5 weeks

The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver-rated questionnaire that assesses the frequency of agitation-related and disruptive behaviors in subjects with dementia. The scale contains 29 behaviors or items organized into four subscales: physically aggressive, physically non-aggressive, verbally aggressive, and verbally non-aggressive. The CMAI is administered by interviewing the caregiver and asking him or her to rate the frequency with which the subject manifests each behavior using a seven-point scale: 1=never (better outcome), 7=several times an hour (worse outcome). The CMAI total score is the sum of the scores for all of the items in the CMAI. CMAI total scores range from a minimum of 29 (better outcome) to a maximum of 203 (worse outcome).

Study Sites (2)

Loading locations...

Similar Trials